irulya.comCrawled Nov 9, 2026
IRulya is investigating LAM-001 for patients with severe pulmonary diseases.
IRulya provides licensed treating physicians with access to investigational products for patient treatment on a case-by-case basis.
IRulya’s lead candidate combines a novel scopolamine formulation with intranasal delivery technology.
The company’s pipeline includes LAM-001, a disease-modifying therapy for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Drayton Wise served as Chief Commercial Officer at Insmed, overseeing global biopharmaceutical and rare disease commercialization for over 25 years. He led the U.S., Europe, and Japan launch of ARIKAYCE, a top 10 non-oncology rare disease product in the United States.
IRulya focuses on developing new pulmonary medicines to address serious, unmet medical needs.
The company invites inquiries for further information.
IRulya was founded to pursue an approach that impacts the underlying disease biology and delivers such therapy directly to the site of disease in the lungs.
IRulya Therapeutics presents at the Craig-Hallum Biotech Catalyst Conference. The clinical-stage biopharmaceutical company develops disease-modifying therapies for underserved diseases. Senior management will engage in a Fireside Chat on October 22, 2026.
Oct 2026ir.irulya.comNews article
IRulya Therapeutics (formerly Quince Therapeutics) advances **LAM-001**, a drug candidate targeting a key biological pathway linked to pulmonary diseases. The company now focuses exclusively on clinical development of the therapy. IRulya’s common stock will begin trading on Nasdaq under the ticker **IRLA** starting October 12, 2026.
Oct 2026ir.irulya.comNews article
Quince Therapeutics hosts a virtual key opinion leader (KOL) event on **September 28, 2026**, to discuss the current treatment landscape for **pulmonary hypertension-associated interstitial lung disease (PH-ILD)** and **bronchiolitis obliterans syndrome (BOS)**. The event will explore the potential role of **LAM-001**, the company’s investigational therapy, in addressing these underserved conditions. Leading experts **Aaron B. Waxman, MD, PhD (Brigham and Women’s Hospital)** and **Paul Yu, MD, PhD (Massachusetts General Hospital)** will participate. Quince Therapeutics develops novel disease-modifying therapies for serious, unmet medical needs.
Sep 2026ir.irulya.comNews article
Quince Therapeutics announces senior management participation in September 2026 investor conferences. The clinical-stage biopharmaceutical company develops novel therapies for serious underserved diseases. This engagement provides an opportunity for investors to learn about the company’s pipeline and progress in drug development.
Sep 2026ir.irulya.comNews article
